127
Participants
Start Date
December 31, 2010
Primary Completion Date
August 31, 2013
Study Completion Date
November 30, 2013
BT061
subcutaneous administration of the monoclonal antibody BT061
Placebo
subcutaneous injection of placebo
Study Site, Ostrava
Study Site, Prague
Study Site, Uherské Hradiste
Study Site, Zlín
Study Site (Berlin 1), Berlin
Study Site (Berlin 2), Berlin
Study Site, Erlangen
Study Site, Frankfurt
Study site, München
Study Site, Nyíregyháza
Study Site, Székesfehérvár
Study Site, Bari
Study Site, Cagliari
Study Site, Chieti
Study Site, Florence
Study Site, Genova
Study site, Milan
Study site, Padua
Study Site, Palermo
Study site, Daugavpils
Study site, Riga
Study Site (Bialystok 2), Bialystok
Study Site, Bialystok
Study Site, Bydgoszcz
Study Site, Elblag
Study site, Gmina Końskie
Study Site, Krakow
Study Site, Lublin
Study Site, Poznan
Study Site, Torun
Study site, Warsaw
Study Site, Wroclaw
Study site (Barcelona 1), Barcelona
Study site (Barcelona 2), Barcelona
Study Site, Bilbao
Study Site (Madrid2), Madrid
Study Site, Madrid
Study Site, Málaga
Study Site, Santander
Lead Sponsor
Biotest
INDUSTRY